Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium

被引：0
|
作者：
Jabbour, Elias [1 ]
Sasaki, Koji [1 ]
Sekeres, Mikkael A. [2 ]
Komrokji, Rami S. [3 ]
Steensma, David P. [4 ]
DeZern, Amy E. [5 ]
Gail, Roboz J. [6 ]
Daver, Naval G. [1 ]
Pemmaraju, Naveen [1 ]
Kadia, Tapan [1 ]
DiNardo, Courtney D. [1 ]
Wang, Xuemei [1 ]
Nogueras-Gonzalez, Graciela [1 ]
Borthakur, Gautam [1 ]
Estrov, Zeev [1 ]
Kantarjian, Hagop M. [1 ]
Garcia-Manero, Guillermo [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Johns Hopkins Univ, Baltimore, MD USA
[6] Weill Cornell Phys, New York, NY USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium
    A M Zeidan
    N Al Ali
    J Barnard
    E Padron
    J E Lancet
    M A Sekeres
    D P Steensma
    A DeZern
    G Roboz
    E Jabbour
    G Garcia-Manero
    A List
    R Komrokji
    Leukemia, 2017, 31 : 1391 - 1397
  • [32] Outcome of Patients (pts) with Acute Myeloid Leukemia (AML) Evolving From Myelodysplastic Syndromes (MDS) Post Hypomethyling Agents (HMA) Failure
    Ghanem, Hady
    Kantarjian, Hagop M.
    Manero, Guillermo Garcia
    Ravandi, Farhad
    Cortes, Jorge E.
    Takahashi, Koichi
    O'BrienMd, Susan M.
    Pierce, Sherry A.
    Kadia, Tapan M.
    Jabbour, Elias J.
    BLOOD, 2012, 120 (21)
  • [33] Cost analysis of long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS).
    Gupta, P
    LeRoy, SC
    Bateman, A
    Morrison, VA
    BLOOD, 1998, 92 (10) : 421A - 421A
  • [34] IMPACT OF MARROW COMPLETE RESPONSE IN THE NATURAL HISTORY OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) TREATED WITH HYPOMETHYLATING AGENTS
    Pierola, A. Alfonso
    Montalban-Bravo, G.
    Takahashi, K.
    Jabbour, E. J.
    Kadia, T.
    Ravandi, F.
    Cortes, J.
    DiNardo, C.
    Daver, N.
    Borthakur, G.
    Pemmaraju, N.
    Konopleva, M.
    Bueso-Ramos, C.
    Pierce, S.
    Kantarjian, H.
    Garcia-Manero, G.
    HAEMATOLOGICA, 2017, 102 : 263 - 264
  • [35] Real-World Use of Hypomethylating Agents (HMA)/Venetoclax Combinations in Patients With Myelodysplastic Neoplasms (MDS) in the Arabian Gulf Region
    Khadadah, Fatima
    Cherif, Honar
    AlOmri, Halima
    Alhuraiji, Ahmad
    Pandita, Ramesh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S370 - S371
  • [36] Real-World Use of Hypomethylating Agents (HMA)/Venetoclax Combinations in Patients with Myelodysplastic Neoplasms (MDS) in the Arabian Gulf Region
    Khadadah, Fatima
    Cherif, Honar
    El Omri, Halima
    Absi, Ahmed
    Merwass, Noor
    Abu Haleeqa, Mohamed I.
    Jaber, Waed
    Alhuraiji, Ahmad
    Pandita, Ramesh
    BLOOD, 2023, 142
  • [37] The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure
    Nazha, Aziz
    Komrokji, Rami S.
    Garcia-Manero, Guillermo
    Barnard, John
    Zimmerman, Cassie
    Najla, Al Ali
    Roboz, Gail J.
    Steensma, David P.
    DeZern, Amy E.
    Jabbour, Elias
    Lee, Sangmin
    Greenberg, Molly D.
    List, Alan F.
    Kantarjian, Hagop M.
    Maciejewski, Jaroslaw P.
    Sekeres, Mikkael A.
    BLOOD, 2014, 124 (21)
  • [38] Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Xiao, Lianchun
    Najla, Al Ali
    Mishra, Asmita
    Padron, Eric
    Lancet, Jeffrey E.
    Bryan, Jeffery
    Prescott, Hillary
    Steensma, David P.
    Sekeres, Mikkael A.
    Roboz, Gail J.
    List, Alan
    Kantarjian, Hagop M.
    Komrokji, Rami S.
    BLOOD, 2013, 122 (21)
  • [39] Long-Term Outcome of Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Single-Institution Experience
    Duque, Adolfo Diaz
    Cabrero, Monica
    Ravandi, Farhad
    Pemmaraju, Naveen
    Borthakur, Gautam
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Kadia, Tapan M.
    Daver, Naval G.
    Jabbour, Elias
    Manero, Guillermo Garcia
    Sasaki, Koji
    BLOOD, 2014, 124 (21)
  • [40] RIGOSERTIB IN COMBINATION WITH AZACITIDINE MODULATES EPIGENETIC PATHWAYS AND CAN OVERCOME CLINICAL RESISTANCE TO HYPOMETHYLATING AGENTS IN MYELODYSPLASTIC SYNDROMES (MDS)
    Chaurasia, P.
    Isoda, F.
    Navada, S.
    Odchimar-Reissig, R.
    Demakos, E. P.
    Reddy, E. P.
    Silverman, L. R.
    LEUKEMIA RESEARCH, 2017, 55 : S121 - S121
12345